Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 1997

View Archived Issues

GI motility stimulants reported by Janssen

Histamine H3 receptor antagonists in development at Gliatech

Yamanouchi reports 5-HT3 agonists for GI indications

New agents for treating encephalopathies from Takeda

New antimigraine drug candidates from Lilly

New endothelin antagonists from Zeneca

Research supports development of Houghten lead compound

Acadesine reduces CABG-associated mortality and morbidity

Hyal receives patent protection for most advanced product

TBC cell adhesion inhibitor enters clinic

Anti-CD11a MAb enters clinical trials for second indication

TheraTech licenses pulmonary delivery devices

Research suggests potential of anti-DNA MeTase antisense compounds

Serotonergic trophic factors offered for licensing

MDI seeks licensees for antiacne compounds

NYU seeks partner for wound-healing protein

Novel antiinflammatory protein available for licensing

MDI offers potential anticancer agent for licensing

CRADA offered for new metastasis gene therapy

Collaborators sought for development of combination chemotherapy approach

NYU seeks partner for novel antibacterial technology

Drug screening technology available for licensing

Development partners sought for novel antimitotic agents

NYU seeks partners for development of potential anticancer/antiinflammatory therapies

NIH offers sterile lyophilization product

Ergo readying first NDA submission

ArQule and Abbott extend collaboration

Axcan/Schwarz U.S. joint venture formed

NESP enters clinical trials

Another clinical trial on PRO-2000 begins

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...